Viz.ai and Cleerly Partner on Heart Disease Evaluation Using Artificial Intelligence
New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier
2 min read
Cleerly : July 24, 2023
Cleerly to Present on AI-Enabled Heart Disease Solutions at SCCT 2023
Executives to discuss Cleerly’s end-to-end solution for precision heart imaging to transform cardiovascular care at annual meeting
Denver – July 25, 2023 -- Cleerly, the company creating a new standard of care for heart disease, announced it will be presenting as a Diamond Partner at the Society of Cardiovascular Computed Tomography’s (SCCT) Annual Scientific Meeting, July 27-30 in Boston, MA at the Hynes Convention Center. Onsite, Cleerly executives will highlight the company’s artificial intelligence (AI)-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized evaluation and treatment of coronary artery disease (CAD). For stronger disease tracking, Cleerly’s analysis goes beyond calcium scoring, stress tests and traditional disease markers to truly identify all types of plaque, disease stage, stenoses, plaque burden, and heart health changes over time.
“We are excited to return to SCCT’s 2023 meeting and join the conversation on cardiovascular computed tomography with the best in the industry,” said James K. Min, MD, FACC, FESC, MSCCT, founder and CEO of Cleerly. “It is an honor to continue to attend this event alongside other leaders and faculty in CT technology and share the work we are doing at Cleerly to transform cardiovascular care and provide personalized heart disease evaluation leveraging AI technology.”
During the event, Cleerly will showcase its end-to-end AI solution for precision heart care as well as the future of cardiovascular computed tomography (CT) technology. Additionally, Cleerly will bring attention to the critical role that precisely quantifying plaque can play in comprehensive heart care and preventing heart attacks. As part of the meeting, Cleerly executives will lead an AI and machine learning cardiovascular CT workshop to discuss plaque analysis and other post-processing evaluation developments within the space. The hands-on workshop allows participants the opportunity to work through a theoretical problem considering how to best develop, adjudicate and deploy AI and machine learning in imaging.
Cleerly will be participating in the following sessions:
Those onsite can learn more about Cleerly at booth 200 or schedule a meeting in Cleerly’s private meeting room at this link: https://cleerlyhealth.com/events/scct2023
Cleerly is the company creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly helps enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: https://www.cleerlyhealth.com.
Download: JPG |
New partnership delivers critical insights to more cardiovascular care teams to identify and define atherosclerosis earlier
Steven Borg joins as CTO, David McGovern as Vice President of Marketing, and Jim Hartman advances to CCO to support company's mission to create a...
CREDENCE and PACIFIC-1 study data demonstrate potential power of AI-QCT ISCHEMIA
Cleerly to Present New Clinical Evidence on AI-Enabled CCTA at ACC.23/WCCResearch shows accuracy and effectiveness of Cleerly’s personalized...
FDA-cleared Cleerly ISCHEMIA will assist healthcare professionals in clinical diagnosis and decision making for coronary artery disease
Study Results Demonstrate the Prominent Effects of Cleerly’s Products on Changing Clinical Management for Patients Suspected of Coronary Artery...